Mark A. Glickman

This profile gathers the share dealings of Mark A. Glickman in Aralez Pharmaceuticals Inc. In total, 10 filings cover trades dated from 5 February 2016 to 19 March 2018.

Both buying and selling appear: 4 purchases worth €63k, against 1 sale worth €6,051. Netting one side against the other leaves €57k of net buying. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 4 option exercises. Since January 2018: no purchases and 1 sale on the market.

Half of the purchases are above €13k and half below. None of the 4 purchases we analysed coincided with buying by another insider of the same company within 30 days.

The latest filing, published on 21 March 2018, reports an open-market sale of €6,051 in Aralez Pharmaceuticals Inc. The last purchase on record was published on 18 May 2016, which is 3,826 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.